TB-500

Overview

TB-500 is a synthetic peptide related to Thymosin Beta-4 (Tβ4), a small protein that occurs naturally in nearly every cell of the body and is one of the most abundant members of the beta-thymosin family. TB-500 is a synthetic fragment associated with the active region of that larger molecule, and it is most often discussed in the context of recovery and tissue repair.

It is important to distinguish the two: Thymosin Beta-4 is the full-length natural protein, while TB-500 is a shorter synthetic construct sold in the research-chemical market. Most of the supporting evidence comes from studies of Thymosin Beta-4 in animal models. Human clinical data specific to TB-500 is limited, and it is not approved by any major regulator for therapeutic use. It is frequently stacked with BPC-157 in recovery-focused protocols.

How it works

Thymosin Beta-4 is best characterized as a G-actin sequestering peptide — it binds monomeric actin inside cells and helps regulate the assembly of the cytoskeleton. Because cytoskeletal remodeling underlies how cells move, this activity is thought to support cell migration to sites of injury.

In preclinical studies, Thymosin Beta-4 has been reported to promote angiogenesis — the formation of new blood vessels — which may aid tissue repair by improving blood flow to damaged areas. Researchers have also described effects on cell migration, reduced inflammation, and, in muscle-injury models, a chemoattractant role that draws muscle-precursor cells toward the site of damage. The precise mechanism of the TB-500 fragment in humans is not established.

Reported benefits

• Faster recovery from muscle, tendon, and ligament injuries (animal data)
• Support for wound healing and skin repair (animal and early clinical data on Thymosin Beta-4)
• Promotion of new blood vessel formation at sites of injury
• Reduced inflammation around damaged tissue
• Greater flexibility and reduced stiffness reported anecdotally in recovery protocols

These are reported effects, not guaranteed outcomes, and much of the evidence is preclinical.

Considerations & side effects

Because human trials specific to TB-500 are lacking, its long-term safety profile is not well characterized. Related work on Thymosin Beta-4 in dermal-healing trials has generally described it as safe and well tolerated, but that does not automatically extend to the fragment sold as TB-500. Reported side effects in practice are generally mild and include injection-site irritation, temporary fatigue or lightheadedness, and nausea.

TB-500 is prohibited in sport by WADA at all times, so any athlete subject to drug testing should avoid it. Product purity also varies widely in the research-chemical market. TB-500 is not a substitute for evaluation and treatment by a qualified clinician.